ангиотензиноген作为心血管和代谢疾病的治疗点
Alan Daugherty1,2,3, Hisashi Sawada1,2,3, Mary B Sheppard1,2,3,4,5
1Saha Cardiovascular Research Center (A.D., H.S., M.B.S., H.S.L.), University of Kentucky, Lexington.
Arteriosclerosis, thrombosis, and vascular biology
|April 4, 2024
概括
向血管增生素 (AGT) 合成为各种疾病提供了一个有前途的治疗策略. 抑制AGT在高血压和动脉样硬化等疾病中显示出好处,突出了其在心血管和代谢健康方面的潜力.
科学领域:
- 生物化学 生物化学
- 心血管科学 心血管科学
- 药理学 药理学是指药理学的学科.
背景情况:
- ангиотензиноген (AGT) 是所有雷宁- ангиотензин系统的前体,但受到的关注比其他成分少.
- 最近的药物开发重点是针对AGT合成,增加了研究兴趣.
- AGT是一种非抑制性胺,具有保存的域和血管酶II序列.
研究的目的:
- 审查最近关于AGT操纵作为治疗方法的研究.
- 突出针对AGT合成的治疗潜力.
- 总结关于各种疾病中AGT抑制的发现.
主要方法:
- 使用Agt-floxed小鼠治疗细胞特异性的AGT缺陷.
- 采用药理方法来抑制肝细胞中的AGT合成.
- 审查对AGT遗传删除或药理抑制的实验研究.
主要成果:
- 在小鼠中Agt的遗传删除带来了发育挑战,需要有条件的淘汰模式.
- 在Agt-floxed小鼠中,可以发现细胞特异性缺陷,从而提供有关心血管疾病的见解.
- 人类对AGT合成的药理抑制是一种正在发展中的方法.
- 在高血压,动脉样硬化,动脉瘤,心肌功能障碍和肝硬化等实验模型中,AGT抑制显示出好处.
结论:
- 通过遗传或药理手段的AGT操纵显示出显著的治疗前景.
- 向AGT合成对一系列心血管和代谢疾病有好处.
- 对AGT结构-功能和新陈代谢的进一步研究是有必要的.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
627
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
627
01:25Antihypertensive Drugs: Direct Renin Inhibitors
616
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
616
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
720
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
720
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
159
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
159